We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

120 hedge funds and large institutions have $439M invested in BioCryst Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 28

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

14% more capital invested

Capital invested by funds: $384M → $439M (+$54.6M)

4% more funds holding

Funds holding: 115 → 120 (+5)

1.07% less ownership

Funds ownership: 85.89% → 84.81% (-1.1%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

77% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $4.83M

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
2.99%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
22
Increased
42
Reduced
28
Closed
17
Calls
$1.1M
Puts
$4.83M
Net Calls
-$3.73M
Net Calls Change
-$7.98M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$23.2M
2
BBA
Baker Bros. Advisors
New York
+$11.7M
3
RCM
RA Capital Management
Massachusetts
+$9.33M
4
GPP
Great Point Partners
Connecticut
+$8.38M
5
DM
Deerfield Management
New York
+$7.56M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$4.82M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.05M
3
Goldman Sachs
Goldman Sachs
New York
-$2.89M
4
UONDDL
University of Notre Dame du Lac
Indiana
-$2.35M
5
PC
Paulson & Co
New York
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$2.36M +$2.3M +450,000 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.94M +$2.41K +470 +0.1%
Morgan Stanley
28
Morgan Stanley
New York
$1.9M +$227K +44,241 +14%
Goldman Sachs
29
Goldman Sachs
New York
$1.89M -$2.89M -563,820 -61%
EU
30
Emory University
Georgia
$1.89M +$371K +72,492 +25%
TCM
31
Tekla Capital Management
Massachusetts
$1.69M +$1.66M +323,255 New
Charles Schwab
32
Charles Schwab
California
$1.68M +$62.8K +12,267 +4%
MIM
33
Monashee Investment Management
Massachusetts
$1.62M – – –
EAM
34
Eventide Asset Management
Massachusetts
$1.52M – – –
ARTA
35
A.R.T. Advisors
New York
$1.34M -$266K -51,950 -17%
Deutsche Bank
36
Deutsche Bank
Germany
$1.33M -$1.36M -264,785 -51%
Renaissance Technologies
37
Renaissance Technologies
New York
$1.19M -$911K -178,000 -44%
LCM
38
Laurion Capital Management
New York
$1.13M +$1.11M +216,162 New
TA
39
Teachers Advisors
New York
$1.06M +$28.1K +5,494 +3%
Swiss National Bank
40
Swiss National Bank
Switzerland
$898K +$292K +57,000 +50%
Allianz Asset Management
41
Allianz Asset Management
Germany
$835K +$214K +41,727 +35%
PVI
42
Pura Vida Investments
New York
$786K +$256K +50,000 +50%
RA
43
Royce & Associates
New York
$755K – – –
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$671K -$70.9K -13,838 -10%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$620K – – –
UBS Group
46
UBS Group
Switzerland
$598K +$259K +50,635 +80%
Two Sigma Investments
47
Two Sigma Investments
New York
$548K -$1.21M -236,466 -69%
Tudor Investment Corp
48
Tudor Investment Corp
Connecticut
$537K +$310K +60,566 +144%
AllianceBernstein
49
AllianceBernstein
Tennessee
$521K -$42K -8,200 -8%
Wells Fargo
50
Wells Fargo
California
$507K +$167K +32,530 +51%
1
2
3 4 5

BCRX Hedge Fund Activity: Q3 2017 in Review

120 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2017, worth a combined $439M — up 14% from $384M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new BCRX positions and 17 closed out — a net gain of 5 holders — while 42 added to existing stakes and 28 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $23.2M. The largest seller was State Street, cutting an estimated $4.82M.

  • 120 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2017, up from 115 in Q2 2017.
  • Funds reported $439M of BioCryst Pharmaceuticals stock for Q3 2017, up 14% quarter-over-quarter.
  • 22 funds opened new BioCryst Pharmaceuticals positions in Q3 2017 and 17 closed out, a net change of +5 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2017 was Janus Henderson Group, an estimated $23.2M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2017 was State Street, an estimated $4.82M sold.

Based on aggregated 13F filings for Q3 2017.